Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook...
-
Upload
abigayle-griffin -
Category
Documents
-
view
215 -
download
0
Transcript of Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook...
![Page 1: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/1.jpg)
Gram-Positives: Focus on MRSA From Bench to Bedside
Andrew E. Simor, MD, FRCPC, FACPSunnybrook Health Sciences Centre
University of Toronto
![Page 2: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/2.jpg)
Disclosures
I have received grants, or served as a consultant on Advisory Boards for:
• Astellas Pharma• BD GeneOhm• Janssen-Ortho• Pfizer Canada• Sepracor Pharmaceuticals
![Page 3: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/3.jpg)
Resistant Gram-Positive Pathogens
MRSAVRE
C. difficile
![Page 4: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/4.jpg)
Staphylococcus aureus
• S. aureus is most common cause of healthcare-associated infections
• MRSA is the major antibiotic-resistant organism in hospitals; CA-MRSA increasing
![Page 5: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/5.jpg)
Annual Deaths in the U.S. for Selected Infectious Diseases
DeLeo and Chambers JCI 2009 adapted from Klevens JAMA 2007
Infectious disease
No. of deaths Year
MRSA 19,000 20051
AIDS 14,561 20072
TB 644 20063
Viral hepatitis
5793 20021
1.Boucher CID 2008; 46(Suppl 5):S344-92. http://www.cdc.gov/hiv/topics/surveillance/basic.htm#ddaids3 http://www.cdc.gov/TB/publications/factsheets/statistics/TBTrends.htm
![Page 6: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/6.jpg)
MRSA in Canada, 1995-2009
0
2
4
6
8
10
12
MR
SA
per
1,0
00 a
dm
issi
ons
Overall Infection Colonization
Simor, Infect Control Hosp Epidemiol 2010; Canadian Nosocomial Infection Surveillance Program
![Page 7: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/7.jpg)
MRSA in Canadian Hospitals
Simor, Infect Control Hosp Epidemiol 2010
![Page 8: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/8.jpg)
MRSA Infections, 2008-09 (30%)
0
10
20
30
40
Skin/Softtissue
SSI Resp Blood Urine Other
%
Canadian Nosocomial Infection Surveillance Program
![Page 9: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/9.jpg)
MRSA in Canadian Hospitals
CANWARD: 10 hospitals, 2008
MRSA accounted for 5% of all clinical isolates (5% blood, 6% respiratory, 12% wound isolates)
Zhanel, Antimicrob Agents Chemother 2010
![Page 10: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/10.jpg)
MRSABloodstream Infections
Location MRSA as a % of S. aureus
bacteremias
U.K.* 36
Ontario† 18
Quebec§ 21
Canada (CANWARD)** 24**Jeyaratnam, BMJ 2008; † QMPLS, 2009; §Institut National de Santé Publique du Québec, 2008; **Adam, Diagn Microbiol Infect Dis 2011
![Page 11: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/11.jpg)
MRSA in Canadian Hospitals, 2010
There were:
approx 36,000 new MRSA patients
11,000 new MRSA infections
2,200 MRSA-related deaths
$250 million excess costs attributable to MRSA
![Page 12: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/12.jpg)
Molecular Epidemiology of CA-MRSA
Otter, Lancet ID, 2010
![Page 13: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/13.jpg)
MRSA in Canada:Evolving Molecular Epidemiology
PFGE type 1995-1999
2004-2007
2008- 2009
CMRSA-2(USA100)
14% 58% 49%
CMRSA-10(USA300)
<1% 17% 32%
Simor, Infect Control Hosp Epidemiol 2010; Simor, IDSA 2010
![Page 14: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/14.jpg)
Provincial Distribution of MRSA Strains (2008-2010)
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
BC n=219 AB n=399 SK/MB n=150 ON n=458 QC n=129 ATL n=267
Province
Per
cent
MR
SA
Isol
ates
CMRSA1
CMRSA2
CMRSA3/6
CMRSA4
CMRSA5
CMRSA7
CMRSA8
CMRSA9
CMRSA10
Others (non-CMRSAs)
Canadian Nosocomial Infection Surveillance Program
![Page 15: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/15.jpg)
CA-MRSA & HA-MRSA MRSA infections by age-groups 2008 surveillance
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
<10 [10-19] [20-29] [30-39] [40-49] [50-59] [60-69] [70-79] >80
Patients' age (years)
Perc
en
tag
e (
%)
CA-MRSA
HA-MRSA
Canadian Nosocomial Infection Surveillance Program
![Page 16: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/16.jpg)
CA-MRSA Epidemiology neonates, children homeless, incarcerated, IVDU MSM, HIV-infected military personnel athletes (contact sports) native aboriginals household contacts veterinarians, livestock handlers
David, Clin Microbiol Rev 2010
![Page 17: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/17.jpg)
Livestock-Associated MRSA
SCCmec IV, PVL-neg Pigs: ST398 (not
typeable by PFGE SmaI) (Voss, Emerg Infect Dis 2005; Khanna, Vet Microbiol 2008; Golding, Emerg Infect Dis 2010)
Horses: CMRSA-5 (USA500; t007) (Weese, Emerg Infect Dis 2005)
![Page 18: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/18.jpg)
MRSA in Domestic Pets
reported in cats, dogs, guinea pigs, parrots
a variety of clones, often HA-MRSA
(Weese, Vet Microbiol 2006; David, Clin Microbiol Rev 2010)
![Page 19: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/19.jpg)
CA-MRSA as a Cause of Healthcare-Associated Infections
• USA400 post-partum infections, NY mastitis, cellulitis, abscesses (Saiman, CID 2003)
• USA300 prosthetic joint infections, SSIs (Kourbatova, Am J Infect Control 2005; Patel, J Clin Microbiol 2007)
• USA300 accounted for 28% healthcare-associated bacteremias, 20% nosocomomial MRSA BSIs, Atlanta, GA (Seybold, CID 2006)
• USA300 transmission in a Canadian Burn unit (McGuire, SHEA 2007)
![Page 20: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/20.jpg)
CA-MRSA in Canadian Hospitals
predominantly SSTI, in younger adults, Western Canada
60% community-associated; 40% healthcare-associated
94% PVL-positive (predominantly CMRSA-10; SCCmec type IV)
Simor, Infect Control Hosp Epidemiol 2010
![Page 21: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/21.jpg)
CA-MRSA: Enhanced Virulence?
associated with severe and recurrent SSTI, often in individuals without predisposing risk factors
associated with necrotizing pneumonia appears to be easily transmitted in
hospitals, households, and the community
![Page 22: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/22.jpg)
CA-MRSAVirulence
• USA 300/400 more virulent than other strains of S. aureus/MRSA in a mouse model of bacteremia
• more resistant to killing by human PMNs
Voyich, J Immunol 2005;Li, PNAS 2009
![Page 23: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/23.jpg)
MRSA USA300 Virulence Factors
David, Clin Microbiol Rev 2010
![Page 24: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/24.jpg)
CA-MRSAVirulence
Panton-Valentine Leukocidin (PVL) -hemolysin (increased expression in
CA-MRSA; -hemolysin antibody protective in mouse model) (Wardenburg, Nature Med 2007)
Argenine catabolic mobile element (ACME; unique to CA-MRSA, S. epidermidis; may help strain evade host response and facilitate colonization) (Goering, J Clin Microbiol 2007)
![Page 25: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/25.jpg)
Gillet, Lancet 2002
PVL Gene and Survival
![Page 26: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/26.jpg)
PVL Gene and Virulence
using isogenic PVL knockout mutants in murine models (subcut abscess, pneumonia) has given conflicting results (Voyich, J Infect Dis 2006; Labandeira-Rey, Science 2007)
PVL does appear to contribute to virulence in a rabbit bacteremia model (An Diep, PLoS ONE 2008)
![Page 27: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/27.jpg)
MRSAImpact
• attributable mortality and morbidity (Whitby, Med J Austr 2001; Cosgrove, Clin Infect Dis 2003)
• prolonged hospital length of stay (Engemann, Clin Infect Dis 2003; Cosgrove, Infect Control Hosp
Epidemiol 2005)
• excess/attributable costs, $14,360 (Kim, Infect Control Hosp Epidemiol 2001)
![Page 28: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/28.jpg)
Impact of MRSA Infections
Infection Mortality (%)
MRSA Bacteremia* 20-35
MRSA Pneumonia† 25-60
* Cosgrove, Clin Infect Dis 2003; Melzer, Clin Infect Dis 2003; Wyllie, BMJ 2006
† Combes, AJRCCM 2004; DeRyke, Chest 2005; Zahar, Clin Infect Dis 2005
![Page 29: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/29.jpg)
Why does antibiotic resistance affect outcome?
• Host factors• Organism virulence• Delay in instituting effective
therapy (or vancomycin less effective)
Bradley, Clin Infect Dis 2002; Paterson, Clin Infect Dis 2004; Kim, Antimicrob Agents Chemother 2008
![Page 30: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/30.jpg)
MRSA Bacteremia in Canadian Hospitals, 2008-09
MRSA bacteremia rates: 0.50 per 1,000 admissions
0.61 per 10,000 patient-days source of bacteremia:
skin, soft tissue, SSI - 36% 1y bacteremia, CA-BSI - 24% pneumonia - 16%
healthcare-associated, 72% community-associated, 28% (CMRSA-2, 49%; CMRSA-10, 32%)
Simor, IDSA 2010
![Page 31: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/31.jpg)
MRSA Bacteremia in Canadian Hospitals, 2008
30-day all-cause mortality: 23% variables associated with mortality:
age > 65 yrs (OR 2.3, 95% CI 1.3-3.9) pneumonia (OR 4.0, 95% CI 2.0-7.8) HA-MRSA (OR 2.3, 95% CI 1.1-4.8)
mortality not associated with PFGE type, PVL gene, or reduced susceptibility to vancomycin (3 isolates with MIC = 2)
Simor, IDSA 2010
![Page 32: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/32.jpg)
MRSA Infection
How does treatment affect outcome?
![Page 33: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/33.jpg)
Vancomycin SusceptibilityBreakpoints in Staphylococci
MIC (µg/ml) Interpretation
2 Susceptible
4-8 Intermediate
16 Resistant
CLSI
![Page 34: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/34.jpg)
Risk factors OR (95% CI) P value
Vancomycin MIC ≥ 2 µg/ml
6.3 (1.2-33.1) 0.03
Retained medical device
10.4 (1.1-104.6) 0.05
MRSA infection at ≥ 2 sites
10.2 (1.7-61.0) 0.01
Predictors of Persistent MRSA Bacteremia (multivariate analysis)
Yoon, J Antimicrob Chemother 2010
![Page 35: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/35.jpg)
Vancomycin MICs and Treatment Outcome in MRSA Bacteremia
0
10
20
30
40
50
60
70
<0.5 1.0 - 2.0
Vancomycin MIC (mg/ml)1
Cli
nic
al
su
cc
es
s (
%)
0
10
20
30
40
50
60
70
0.5 1 2
Vancomycin MIC (mg/ml)2
Clin
ical
su
cces
s (%
)1 Sakoulas, J Clin Microbiol 20042 Moise-Broder, Clin Infect Dis 2004
p=0.01
p=0.003
![Page 36: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/36.jpg)
MRSA PneumoniaOutcome
158 cases MRSA pneumonia (HAP/VAP)
28-day mortality: 32% mortality increased
with vancomycin MIC > 1.5 µg/ml
Haque, Chest 2010
![Page 37: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/37.jpg)
What about hVISA?
hVISA (heteroresistant): MIC susceptible (< 4 µg/ml), but with a resistant sub-population; detected by PAP-AUC
preliminary step towards development of VISA (Hiramatsu, Lancet ID 2001)
may be associated with treatment failure (Sakoulas, Antimicrob Agents Chemother 2005)
![Page 38: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/38.jpg)
van Hal, Antimicrob Agents Chemother 2011
Impact of hVISA: A Meta-Analysis
![Page 39: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/39.jpg)
Canadian MRSA and Vancomycin
Adam, Antimicrob Agents Chemother 2010
![Page 40: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/40.jpg)
Vancomycin and Treatment Failure
• higher vancomycin MICs associated with worse outcome
• thus: recommendations to use higher vancomycin doses (target trough: 15-20 µg/ml) (Liu, Clin Infect Dis 2011)
• but, higher troughs not associated with better outcome; associated with increased nephrotoxicity (Hidayat, Arch Intern Med 2006)
![Page 41: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/41.jpg)
Liu, Clin Infect Dis 2011
![Page 42: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/42.jpg)
Liu, Clin Infect Dis 2011
MRSA Treatment Guidelines:
Evidence-Based?
![Page 43: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/43.jpg)
Can we do a better job of preventing MRSA
infection?
![Page 44: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/44.jpg)
MRSA Infection Control Strategies
• contact precautions• screening• decolonization
![Page 45: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/45.jpg)
Evidence for Effectiveness of Active Surveillance + Contact Precautions
• ecological studies (Verhoef, EJCMID 1999; Tiemersma, Emerg Infect Dis 2004)
• observational/quasi-experimental studies (Jernigan, Am J Epidemiol 1996; Chaix, JAMA 1999; Huang, Clin Infect Dis 2006; Robicsek, Ann Intern Med 2008)
• mathematical models (Bootsma, PNAS 2006)
![Page 46: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/46.jpg)
PCR vs. Chromogenic Media prospective, cross-
over study, 2 hospital wards, UK
median time to report MRSA: 47 hrs vs. 21 hrs (culture vs. PCR; p<0.001)
no reduction in MRSA transmissionAldeyab, J Hosp Infect 2009
![Page 47: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/47.jpg)
MRSA Decolonization
decolonization to prevent staphylococcal SSI (Bode, N Engl J Med 2010)
observational studies with mupirocin or other agents as part of infection control measures (Hill, J Antimicrob Chemother 1998; Strausbaugh, ICHE 1992; Sandri, ICHE 2006; Ridenour, ICHE 2007; Bowler, ICHE 2010)
interrupted time-series analysis in 2 UK ICUs: chlorhexidine gluconate baths reduced MRSA transmission, but emergence of strains with reduced susceptibility to CHG (Batra, Clin Infect Dis 2010)
![Page 48: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/48.jpg)
MRSA:The Dutch Experience
• national “search and destroy policy”
screening patients, staff
strict isolation
decolonization
environmental cleaning
outbreak controlVerhoef, EJCMID 1999; van Trijp, Infect Control Hosp Epidemiol 2007
![Page 49: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/49.jpg)
MRSA Bacteremia - England
Pearson, J Antimicrob Chemother 2009
![Page 50: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/50.jpg)
MRSA in Canada - 2011
• Infectious morbidity of HA-MRSA and CA-MRSA continues to increase
• Need to better understand variables associated with treatment failure
• Need to better understand and implement effective strategies for MRSA infection prevention
![Page 51: Gram-Positives: Focus on MRSA From Bench to Bedside Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto.](https://reader036.fdocuments.us/reader036/viewer/2022070415/56649d095503460f949db11a/html5/thumbnails/51.jpg)
The End